Zydus receives final approval from the USFDA for Acyclovir Cream

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Acyclovir Cream, 5% (USRLD: Zovirax® Cream).

Acyclovir belongs to a class of medications known as antivirals. Acyclovir cream is used to treat cold sores (fever blisters; blisters that are caused by a virus called herpes simplex) on the face or lips. The product will be launched shortly in the US market. The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India).

Acyclovir Cream, 5% had annual sales of USD 16.9 mn in the United States (IQVIA MAT Dec. 2022).

The group now has 348 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 472.15 as compared to the previous close of Rs. 465.55. The total number of shares traded during the day was 25577 in over 1206 trades.

The stock hit an intraday high of Rs. 475.45 and intraday low of 463.35. The net turnover during the day was Rs. 12055302.00.

(*as of 31st December 2022)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals FinalApproval USFDA AcyclovirCream